Floatz logo

Palbociclib

Recurrent Extragonadal Non-seminomatous Germ Cell Tumor

Abramson Cancer Center at Penn MedicineSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Recurrent Extragonadal Non-seminomatous Germ Cell Tumor cohort.

Asset / SponsorPhaseRating
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
ETOPOSIDE
Nabil Adra
Phase 2CCC
Bms-907351
Jennifer King
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Nasser Hanna, M.D.
Phase 2CCC

View all 9 →

Same molecule, other indications

Palbociclib is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
ovarian carcinomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →